Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-sulphocysteine is a naturally occurring, endogenous amino acid derivative formed when sulfur metabolism is disrupted, such as in molybdenum cofactor deficiency or sulfite oxidase deficiency. It belongs to the class of organic compounds known as s-conjugated L-cysteines, where the sulfur atom of L-cysteine is substituted with a sulfo group. Structurally, it is a thiosulfate and an analog of glutamate. Mechanistically, S-sulphocysteine acts as a potent agonist at N-methyl-D-aspartate (NMDA) receptors in the central nervous system, leading to increased calcium influx and downstream excitotoxic signaling that can result in neurotoxicity and neuronal damage. Elevated levels are diagnostic markers for certain metabolic disorders affecting sulfur metabolism[5][6]. It has no approved pharmaceutical use but plays an important role as a biomarker and mediator of toxicity in rare genetic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-sulphocysteine.